0
1
OCS-01 targets diabetic macular edema (DME) via topical delivery.
2
It utilizes OPTIREACH technology for enhanced efficacy.
3
Existing DME treatments often lead to low patient compliance.
4
OCS-05 aims to treat acute optic neuritis with neuroprotective benefits.
5
Recent trials show significant improvements in visual acuity and retinal health with OCS-
6
7
The importance of early treatment in DME for better patient outcomes is underscored.
8
Plans for FDA meetings for potential registration of OCS-05 are underway.
